Reclast (zoledronic acid) is a medication that the Food and Drug Administration (FDA) has approved for preventing and treating osteoporosis in females after menopause, males, and individuals who take ...
Zoledronic acid 5 mg/100 mL bottle; solution for IV infusion. Paget’s disease of bone is characterized by greatly increased and disorderly bone remodeling. Excessive osteoclastic bone resorption is ...
WASHINGTON, Aug 17 (Reuters) - Swiss drugmaker Novartis AG said on Friday it had won U.S. approval to sell the first once-a-year treatment for the bone-thinning disease osteoporosis. Sign up here. The ...
Zoledronic acid is effective for reducing hip fracture risk among postmenopausal women with osteoporosis. Zoledronic acid is effective for reducing hip fracture risk among postmenopausal women with ...
WASHINGTON (Reuters) - Swiss drugmaker Novartis A said Friday it had won U.S. approval to sell the first once-a-year treatment for the bone-thinning disease osteoporosis. Sign up here. The drug, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results